Dissecting global protective immune responses to dengue virus
Research type
Research Study
Full title
Dissecting global protective immune responses to dengue virus at single cell resolution
IRAS ID
262888
Contact name
Sarah Teichmann
Contact email
Sponsor organisation
Genome Research Limited, operating as the Wellcome Sanger Institute
Duration of Study in the UK
1 years, 9 months, 1 days
Research summary
Dengue virus (DV) infects 390 million people each year (Bhatt S. et al. 2013). Tropical countries, including Thailand, are most affected by this mosquito-borne viral illness. The disease greatly impacts the country, both on a social and economic level, leading to increased healthcare spending, and school/ work absence. Currently, there is no specific treatment. The only approved vaccine has limited efficacy and its use in young children is prohibited (Hadinegoro SR. et al. 2015). Therefore, a better vaccine and therapeutic strategies are urgently needed. To better design a vaccine, fundamental knowledge of the natural protective immune response against DV is critical. By examining blood cells from people who have had DV infection without symptoms (asymptomatic DV infection), we can gain insights that will inform strategies for effective vaccine design against DV. We will use a cutting-edge technology, single-cell RNA sequencing, to dissect the global protective immune response to DV. Ultimately this improved understanding will hopefully lead to better preventative or therapeutic approaches to DV infection.
REC name
North East - York Research Ethics Committee
REC reference
19/NE/0170
Date of REC Opinion
14 May 2019
REC opinion
Favourable Opinion